CJC-1295 vs. Ipamorelin 2026: Which Is the GHRH and Which Is the GHRP
CJC-1295 vs ipamorelin is the same structural comparison as sermorelin vs ipamorelin — different mechanisms, different roles, almost always used together rather than as alternatives. CJC-1295 sits on the GHRH side; ipamorelin sits on the GHRP side. The combo produces synergistic GH release that neither molecule produces alone.
What changes vs the sermorelin comparison is which GHRH variant you're pairing. CJC-1295 comes in two flavors: 'with DAC' (a Drug Affinity Complex extending half-life to 7-10 days, allowing once-weekly dosing) and 'no DAC' (Modified GRF 1-29, ~30-minute half-life, daily dosing). Both pair with ipamorelin; the choice is dosing convenience vs pulse-pattern preference.
If you're new to peptide therapy and your clinician is presenting CJC-1295 + ipamorelin as the protocol, this guide explains why they're paired, what the DAC choice means, and what the combo costs across telehealth, specialty clinic, and 503A direct paths.
Today's best sample deals for CJC-1295 or Ipamorelin
CJC-1295 vs. Ipamorelin: side-by-side comparison
| Dimension | CJC-1295 | Ipamorelin |
|---|---|---|
| Mechanism | GHRH receptor agonist | GHRP / ghrelin-receptor agonist |
| Receptor | GHRH receptor (pituitary) | Ghrelin / GHS receptor (pituitary) |
| Half-life | ~7-10 days (with DAC) / ~30 min (no DAC) | ~2 hours |
| Dosing convention | Weekly (with DAC) / daily (no DAC) | Daily, evening |
| Effect pattern | Sustained (with DAC) / pulse (no DAC) | Amplifies pulse |
| Solo use case | Possible — smaller GH response than combo | Possible — smaller GH response than combo |
| Combined use case | Standard clinical protocol | Standard clinical protocol |
| Regulatory status | Removed from Cat-2 Sept 2024; PCAC review pending | Removed from Cat-2 Sept 2024; PCAC review pending |
Pairing CJC-1295 with ipamorelin is the same play as sermorelin with ipamorelin — a GHRH for the release signal, a GHRP for the pulse. The CJC-vs-sermorelin choice is dosing convenience and pharmacokinetic preference, not synergy.
Cost comparison: CJC-1295 vs. Ipamorelin in 2026
Real 2026 prices from active programs across savings cards, manufacturer cash-pay channels, retail pharmacies, and compounded alternatives.
| Cost path | CJC-1295 | Ipamorelin |
|---|---|---|
| Telehealth combo bundle | $129-279 / mo (DAC) / $99-229 / mo (no DAC) | Bundled with CJC at same price |
| Specialty clinic combo | $250-500 / mo (DAC) / $200-450 / mo (no DAC) | Bundled with CJC |
| 503A direct | $70-200 / vial (DAC) / $60-180 / vial (no DAC) | $50-160 / vial |
When to choose CJC-1295 vs. Ipamorelin
Choose CJC-1295 if:
- ✓You don't have a current GHRH in your protocol
- ✓You want once-weekly dosing for adherence (DAC variant)
- ✓You want pulse-pattern GH stimulation (no-DAC variant)
- ✓Your clinician's protocol specifies CJC-1295 over sermorelin
Choose Ipamorelin if:
- ✓You don't have a current GHRP in your protocol
- ✓You're already on a GHRH (CJC-1295 or sermorelin) and need to add the GHRP side
- ✓Your prior GHRP caused side effects (appetite, cortisol drift) — ipamorelin is the cleanest selective GHRP
Clinical evidence behind CJC-1295 vs. Ipamorelin
Both molecules have established 503A clinical use. CJC-1295's pharmacokinetics are well-characterized in published literature. Ipamorelin's selectivity profile is established. The GHRH + GHRP combo synergy is well-supported mechanistically. Long-term outcome data is primarily clinical-practice based rather than from large RCTs.
Top providers that prescribe CJC-1295 or Ipamorelin
Providers we've verified for clinically appropriate CJC-1295 or Ipamorelin pathways. Pricing and availability vary by state and insurance.
Specialty clinic with the deepest peptide protocols in the US — sermorelin, ipamorelin, CJC-1295, BPC-157, full lab panels, hormone-optimization context.
- ✓ Deepest peptide formulary of any US telehealth clinic
- ✓ Lab-first protocols with quarterly monitoring
- ✓ Physician-designed peptide stacks (not algorithmic)
- − Premium pricing — initial intake $300-600
- − No public affiliate network — direct partnership only
- − Wait list periodically opens and closes
Hormone-optimization clinic with full peptide formulary — sermorelin, ipamorelin, CJC-1295, GHK-Cu, plus TRT integration.
- ✓ Full clinical peptide formulary
- ✓ Telehealth in all 50 states
- ✓ TRT + peptide integrated practice
- − No insurance — cash-pay model
- − Premium pricing for full panels
- − Direct affiliate only — no public network
Mainstream telehealth bringing sermorelin and ipamorelin into the standard hormone-optimization protocol — accessible pricing, simple intake.
- ✓ Most accessible peptide therapy entry pricing
- ✓ Subscription model includes labs + clinician
- ✓ CJ Affiliate partner — public affiliate program
- − Limited to subset of clinical-track peptides
- − Less protocol depth than Marek/Defy
- − Subscription pressure on cancellation
CJC-1295 vs. Ipamorelin: frequently asked
Why pair CJC-1295 with ipamorelin specifically (vs another GHRP)?
Ipamorelin is the cleanest selective GHRP — pituitary-selective, no cortisol or prolactin spike, no appetite stimulation. Older GHRPs (GHRP-2, GHRP-6) reliably amplify GH pulse but introduce off-target effects. Ipamorelin produces the pulse cleanly, which is why modern clinical protocols default to it.
CJC-1295 with DAC or no DAC — which goes with ipamorelin?
Either. Both pair with ipamorelin. With DAC: weekly CJC + daily ipamorelin (CJC sets sustained baseline; daily ipamorelin pulses on top). No DAC: daily CJC + daily ipamorelin (both pulse-pattern, dosed together).
Can I add ipamorelin to an existing CJC-1295 protocol?
Yes, with clinician oversight. The addition is straightforward and produces meaningfully larger GH response than CJC alone. Most clinical protocols add ipamorelin from day one rather than adding it later.
Which side has more side effects, CJC or ipamorelin?
Both have mild side-effect profiles. CJC with DAC has slightly more water retention because of the sustained elevation. Ipamorelin is the cleanest GHRP — no cortisol spike, no appetite stimulation. Combined side-effect burden is small under physiologic dosing.
How does this compare to MK-677?
MK-677 is an oral non-peptide ghrelin/GHS receptor agonist that produces sustained 24-hour GH/IGF-1 elevation. CJC-1295 + ipamorelin is the injectable clinical alternative via a legitimate Rx path. We do not recommend MK-677 for the regulatory reasons covered on its own page.
Do I need both, or can I get the same effect with sermorelin alone?
Solo sermorelin (or solo CJC-1295) produces a meaningful but smaller GH response than the combo with ipamorelin. The synergy is the structural reason for pairing. If cost is the constraint, talk to your clinician about whether a starter protocol on sermorelin alone makes sense before adding ipamorelin.